Table 1.
Baseline clinical and laboratory characteristics of the patients
|
Examined parameter
|
Baseline value
|
|
| Sex as M/F, n (%) | 71/45 (61.2) | |
| Age in yr1 | 59 ± 13 | |
| BMI, kg/m2 | 27.5 ± 5.0 | |
| Liver disease etiology, n (%) | ||
| Chronic hepatitis B | 25 (21.6) | |
| Chronic hepatitis C | 20 (17.2) | |
| Alcohol abuse | 35 (30.2) | |
| NAFLD | 20 (17.2) | |
| Autoimmune hepatitis | 5 (4.3) | |
| Other | 11 (9.5) | |
| CTP class, n (%) | ||
| A | 78 (67.2) | |
| B | 33 (28.4) | |
| C | 5 (4.4) | |
| CTP score | 6.2 ± 1.6 | |
| MELD score | 11.0 ± 3.9 | |
| Decompensated cirrhosis, n (%) | 61 (52.6) | |
| History of HE, n (%) | 37 (31.9) | |
| Ascites, n (%) | 56 (48.3) | |
| Bilirubin in mg/dL | 1.3 ± 0.9 | |
| Creatinine in mg/dL | 1.0 ± 1.2 | |
| Albumin in g/L | 41.0 ± 4.0 | |
| Platelet count as × 109/L | 121 ± 49 | |
| INR | 1.3 ± 0.3 | |
1
Quantitative variables are expresses as mean ± SD.
BMI: Body mass index; CTP: Child-Turcotte-Pugh; F: Female; HE: Hepatic encephalopathy; INR: International normalized ratio; M: Male; MELD: Model for end-stage liver disease; NAFLD: Nonalcoholic fatty liver disease.